Company: BDRX
Filing Date: 2025-01-28
Form Type: 424B3
Source: 0001214659-25-001409
Chunk: 353

Company: Biodexa Pharmaceuticals Plc
Filing Date: 2025-01-28
Form: 424B3
Chunk 353
---
        – |   |     |   |        – |   |     |   |        – |   |
| Adhera Assignment and Exchange Agreement |     |   |  2,275,050 |   |     |   |        – |     |   |        – |   |     |   |        – |   |     |   |        – |   |
| Exercised                                |     |   |   (155,461 | ) |     |   |        – |     |   |  (32,327 | ) |     |   |  (48,491 | ) |     |   | (415,043 | ) |
| As at December 31, 2023                  |     |   |  4,186,226 |   |     |   |        – |     |   |        – |   |     |   |        – |   |     |   |        – |   |
| Exercised                                |     |   | (2,361,865 | ) |     |   |        – |     |   |        – |   |     |   |        – |   |     |   |        – |   |
| Lapsed                                   |     |   |       (163 | ) |     |   |        – |     |   |        – |   |     |   |        – |   |     |   |        – |   |
| Warrant inducement May 2024              |     |   |          – |   |     |   |  931,585 |     |   |        – |   |     |   |        – |   |     |   |        – |   |
| As at June 30, 2024 (unaudited)          |     |   |  1,824,198 |   |     |   |  931,585 |     |   |        – |   |     |   |        – |   |     |   |        – |   |

The Series A, Series
B and Series C warrants are exercisable on an ‘alternative cashless basis’ effectively allowing the holders to exercise for
nil consideration.

Ordinary and deferred
shares were recorded as equity.

| F-17 |

| Schedule of ordinary and deferred 
 shares                            |     |                                                         |     |               |     |               |     |               |     |                 |     |                     |
|